You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)獨家代理吉利德五個產品
阿思達克 02-10 09:15

華潤醫藥(03320.HK)旗下全資子公司華潤醫藥商業宣布,獨家代理吉利德科學公司五個產品,將持續深化與吉利德的戰略合作。華潤醫藥為吉利德在中國的全面戰略合作夥伴。截至目前,華潤醫藥商業共獨家進口代理了吉利德的五個產品,包括舒發泰(抗愛滋病藥物)、韋立得(新一代乙肝抗病毒藥)、維帕他韋(丙肝新藥,吉二代)、丙通沙(丙肝新藥,吉三代)及必妥維(歷史上最強效的HIV整合(酉每)抑制劑)。

另外,近日吉利德及其在研藥物Remdesivir(瑞德西韋)作為治療新型冠狀病毒的可能有效治療藥物備受關注。目前,吉利德正與中國衛生當局密切合作。2月6日,瑞德西韋正式被用於武漢新型冠狀病毒肺炎患者治療。吉利德自2016年進入中國進行商業運營,共有八款創新藥在中國上市,覆蓋丙肝、乙肝和愛滋病等抗病毒領域,其中五個產品則由華潤醫藥獨家進口代理。華潤醫藥商業早於2018年11月與吉利德簽署了雙方全面戰略合作協定,華潤醫藥商業承接抗愛滋病藥物Truvada(舒發泰)的全國銷售業務,以及未來吉利德在中國上市的抗病毒性傳染病藥物的進口總代理。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account